MapLight Therapeutics: Catalyst4 buys 1,209,225 shares
Catalyst4, Inc., reported as a 10% owner of MapLight Therapeutics, Inc., purchased a total of 1,209,225 shares of Voting Common Stock in open market or private transactions from July 28–30, 2026.
Rhea-AI Filing Summary
Catalyst4, Inc., reported as a 10% owner of MapLight Therapeutics, Inc., purchased a total of 1,209,225 shares of Voting Common Stock in open market or private transactions from July 28–30, 2026. The purchases included 1,000,000 shares at $13.0000 per share and additional shares at $12.6300 and weighted-average prices within ranges of $10.295–$11.28 and $11.31–$12.00 per share. The shares are held of record by Catalyst4, whose board members share voting and dispositive power and each disclaims beneficial ownership; the trades were not marked as made under a Rule 10b5-1 trading plan.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Voting Common Stock F2 | 1,000,000 | $13.00 | $13.00M |
| Purchase | Voting Common Stock F2 | 3,000 | $12.63 | $38K |
| Purchase | Voting Common Stock F1, F2 | 141,088 | $10.7416 | $1.52M |
| Purchase | Voting Common Stock F3, F2 | 65,137 | $11.6891 | $761K |
Footnotes (3)
- F1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.295 to $11.28, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (3) to this Form 4.
- F2. The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein.
- F3. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.31 to $12.00, inclusive.
Key Figures
Key Terms
weighted average price financial
voting and dispositive power regulatory
disclaims beneficial ownership regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider activity did Catalyst4 report in MapLight Therapeutics (MPLT) stock?
Were Catalyst4’s MPLT trades made under a Rule 10b5-1 trading plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.